B cell-specific deficiencies in mTOR limit humoral immune responses

Journal of Immunology

Volumn 191, Issue 4, 2013, Pages 1692-1703

  Zhang, Shuling ^a   Pruitt, Margaret ^a   Tran, Dena ^a   Bois, Wendy Du ^a   Zhang, Ke ^a   Patel, Rushi ^a   Hoover, Shelley ^a   Mark Simpson, R ^a   Simmons, John ^a   Gary, Joy ^a   Snapper, Clifford M ^b   Casellas, Rafael ^a,c   Mock, Beverly A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; BACTERIAL PROTEIN; HAPTEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; MAMMALIAN TARGET OF RAPAMYCIN; PN14 PROTEIN; PROTEIN KINASE B; RNA; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE REARRANGEMENT; GENETIC TRANSFECTION; GERMINAL CENTER; HUMORAL IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOREGULATION; KNOCKOUT MOUSE; MORTALITY; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC HYPERMUTATION; SPLEEN; STREPTOCOCCUS PNEUMONIAE; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIBODY DIVERSITY; ANTIBODY FORMATION; B-LYMPHOCYTES; BACTERIAL CAPSULES; CELL LINEAGE; CYTIDINE DEAMINASE; ENZYME ACTIVATION; GENE KNOCK-IN TECHNIQUES; GERMINAL CENTER; HAPTENS; HOUSING, ANIMAL; IMMUNIZATION; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; MICE; MICE, KNOCKOUT; NITROPHENOLS; PHENYLACETATES; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; SPLEEN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TOR SERINE-THREONINE KINASES;

EID: 84881399035     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201767     Document Type: Article

References (56)

1. Laplante, M., and D. M. Sabatini. 2009. mTOR signaling at a glance. J. Cell Sci. 122: 3589-3594.
2. Zoncu, R., A. Efeyan, and D. M. Sabatini. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12: 21-35.
3. Cutler, C., and J. H. Antin. 2004. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant. 34: 471-476.
4. Xu, X., L. Ye, K. Araki, and R. Ahmed. 2012. mTOR, linking metabolism and immunity. Semin. Immunol. 24: 429-435.
5. Säemann, M. D., and G. Remuzzi. 2009. Transplantation: time to rethink immunosuppression by mTOR inhibitors? Nat. Rev. Nephrol. 5: 611-612.
6. Limon, J. J., and D. A. Fruman. 2012. Akt and mTOR in B Cell Activation and Differentiation. Front Immunol 3: 228.
7. Page, A. J., M. L. Ford, and A. D. Kirk. 2009. Memory T-cell-specific therapeutics in organ transplantation. Curr. Opin. Organ Transplant. 14: 643-649.
8. Singh, K., N. Kozyr, L. Stempora, A. D. Kirk, C. P. Larsen, B. R. Blazar, and L. S. Kean. 2012. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am. J. Transplant. 12: 1441-1457.
9. Zhang, S., J. A. Readinger, W. DuBois, M. Janka-Junttila, R. Robinson, M. Pruitt, V. Bliskovsky, J. Z. Wu, K. Sakakibara, J. Patel, et al. 2011. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood 117: 1228-1238.
10. Lu, L., X. F. Qian, J. H. Rao, X. H. Wang, S. G. Zheng, and F. Zhang. 2010. Rapamycin promotes the expansion of CD4(+) Foxp3(+) regulatory T cells after liver transplantation. Transplant. Proc. 42: 1755-1757.
11. Fortun, J., P. Martin-Davila, J. Pascual, C. Cervera, A. Moreno, J. Gavalda, J. M. Aguado, P. Pereira, M. Gurguí, J. Carratala, et al; RESITRA Transplant Network. 2010. Immunosuppressive therapy and infection after kidney transplantation. Transpl. Infect. Dis. 12: 397-405.
12. Kulkarni, S., R. Powles, J. Treleaven, U. Riley, S. Singhal, C. Horton, B. Sirohi, N. Bhagwati, S. Meller, R. Saso, and J. Mehta. 2000. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 95: 3683-3686.
13. Reich, G., M. Y. Mapara, P. Reichardt, B. Dörken, and G. Maschmeyer. 2001. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 27: 525-529.
14. Goodnow, C. C., C. G. Vinuesa, K. L. Randall, F. Mackay, and R. Brink. 2010. Control systems and decision making for antibody production. Nat. Immunol. 11: 681-688.
15. Moser, K., D. M. Wong, and R. A. Manz. 2011. Antibody memory: a question of life or death beyond the germinal center. Immunol. Cell Biol. 89: 164-166.
16. Rickert, R. C., J. Roes, and K. Rajewsky. 1997. B lymphocyte-specific, Cremediated mutagenesis in mice. Nucleic Acids Res. 25: 1317-1318.
17. Longerich, S., U. Basu, F. Alt, and U. Storb. 2006. AID in somatic hypermutation and class switch recombination. Curr. Opin. Immunol. 18: 164-174.
18. Maul, R. W., and P. J. Gearhart. 2010. AID and somatic hypermutation. Adv. Immunol. 105: 159-191.
19. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-563.
20. Di Noia, J. M., and M. S. Neuberger. 2007. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76: 1-22.
21. Li, Z., C. J. Woo, M. D. Iglesias-Ussel, D. Ronai, and M. D. Scharff. 2004. The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev. 18: 1-11.
22. Peled, J. U., F. L. Kuang, M. D. Iglesias-Ussel, S. Roa, S. L. Kalis, M. F. Goodman, and M. D. Scharff. 2008. The biochemistry of somatic hypermutation. Annu. Rev. Immunol. 26: 481-511.
23. Kracker, S., and A. Durandy. 2011. Insights into the B cell specific process of immunoglobulin class switch recombination. Immunol. Lett. 138: 97-103.
24. Pan-Hammarström, Q., Y. Zhao, and L. Hammarström. 2007. Class switch recombination: a comparison between mouse and human. Adv. Immunol. 93: 1-61.
25. Stavnezer, J., J. E. Guikema, and C. E. Schrader. 2008. Mechanism and regulation of class switch recombination. Annu. Rev. Immunol. 26: 261-292.
26. Hasbold, J., L. M. Corcoran, D. M. Tarlinton, S. G. Tangye, and P. D. Hodgkin. 2004. Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation. Nat. Immunol. 5: 55-63.
27. Rush, J. S., M. Liu, V. H. Odegard, S. Unniraman, and D. G. Schatz. 2005. Expression of activation-induced cytidine deaminase is regulated by cell division, providing a mechanistic basis for division-linked class switch recombination. Proc. Natl. Acad. Sci. USA 102: 13242-13247.
28. Kovalchuk, A. L., W. duBois, E. Mushinski, N. E. McNeil, C. Hirt, C. F. Qi, Z. Li, S. Janz, T. Honjo, M. Muramatsu, et al. 2007. AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements. J. Exp. Med. 204: 2989-3001.
29. Snapper, C. M. 2006. Differential regulation of protein- and polysaccharidespecific Ig isotype production in vivo in response to intact Streptococcus pneumoniae. Curr. Protein Pept. Sci. 7: 295-305.
30. Polack, F. P., S. J. Hoffman, G. Crujeiras, and D. E. Griffin. 2003. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 9: 1209-1213.
31. Yamamoto, M., T. Nojima, K. Hayashi, R. Goitsuka, K. Furukawa, T. Azuma, and D. Kitamura. 2004. BASH-deficient mice: limited primary repertoire and antibody formation, but sufficient affinity maturation and memory B cell generation, in anti-NP response. Int. Immunol. 16: 1161-1171.
32. Maccarthy, T., S. Roa, M. D. Scharff, and A. Bergman. 2009. SHMTool: a webserver for comparative analysis of somatic hypermutation datasets. DNA Repair (Amst.) 8: 137-141.
33. Rada, C., J. M. Di Noia, and M. S. Neuberger. 2004. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/Tfocused phase of somatic mutation. Mol. Cell 16: 163-171.
34. Kitamura, T., Y. Koshino, F. Shibata, T. Oki, H. Nakajima, T. Nosaka, and H. Kumagai. 2003. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp. Hematol. 31: 1007-1014.
35. Delgado, M. F., S. Coviello, A. C. Monsalvo, G. A. Melendi, J. Z. Hernandez, J. P. Batalle, L. Diaz, A. Trento, H. Y. Chang, W. Mitzner, et al. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15: 34-41.
36. Colino, J., and C. M. Snapper. 2007. Dendritic cell-derived exosomes express a Streptococcus pneumoniae capsular polysaccharide type 14 cross-reactive antigen that induces protective immunoglobulin responses against pneumococcal infection in mice. Infect. Immun. 75: 220-230.
37. Schrader, C. E., S. P. Bradley, J. Vardo, S. N. Mochegova, E. Flanagan, and J. Stavnezer. 2003. Mutations occur in the Ig Smu region but rarely in Sgamma regions prior to class switch recombination. EMBO J. 22: 5893-5903.
38. Dunnick, W., G. Z. Hertz, L. Scappino, and C. Gritzmacher. 1993. DNA sequences at immunoglobulin switch region recombination sites. Nucleic Acids Res. 21: 365-372.
39. Petersen, S., R. Casellas, B. Reina-San-Martin, H. T. Chen, M. J. Difilippantonio, P. C. Wilson, L. Hanitsch, A. Celeste, M. Muramatsu, D. R. Pilch, et al. 2001. AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching. Nature 414: 660-665.
40. Nagaoka, H., M. Muramatsu, N. Yamamura, K. Kinoshita, and T. Honjo. 2002. Activation-induced deaminase (AID)-directed hypermutation in the immunoglobulin Smu region: implication of AID involvement in a common step of class switch recombination and somatic hypermutation. J. Exp. Med. 195: 529-534.
41. Takizawa, M., H. Tolarová, Z. Li, W. Dubois, S. Lim, E. Callen, S. Franco, M. Mosaico, L. Feigenbaum, F. W. Alt, et al. 2008. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J. Exp. Med. 205: 1949-1957.
42. Janes, M. R., and D. A. Fruman. 2009. Immune regulation by rapamycin: moving beyond T cells. Sci. Signal. 2: pe25.
43. Baracho, G. V., A. V. Miletic, S. A. Omori, M. H. Cato, and R. C. Rickert. 2011. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr. Opin. Immunol. 23: 178-183.
44. Orthwein, A., A. M. Patenaude, B. Affar, A. Lamarre, J. C. Young, and J. M. Di Noia. 2010. Regulation of activation-induced deaminase stability and antibody gene diversification by Hsp90. J. Exp. Med. 207: 2751-2765.
45. Dengler, H. S., G. V. Baracho, S. A. Omori, S. Bruckner, K. C. Arden, D. H. Castrillon, R. A. DePinho, and R. C. Rickert. 2008. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat. Immunol. 9: 1388-1398.
46. Omori, S. A., M. H. Cato, A. Anzelon-Mills, K. D. Puri, M. Shapiro-Shelef, K. Calame, and R. C. Rickert. 2006. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25: 545-557.
47. Jacinto, E., V. Facchinetti, D. Liu, N. Soto, S. Wei, S. Y. Jung, Q. Huang, J. Qin, and B. Su. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137.
48. Sernández, I. V., V. G. de Yébenes, Y. Dorsett, and A. R. Ramiro. 2008. Haploinsufficiency of activation-induced deaminase for antibody diversification and chromosome translocations both in vitro and in vivo. PLoS ONE 3: e3927.
49. Fagarasan, S., M. Muramatsu, K. Suzuki, H. Nagaoka, H. Hiai, and T. Honjo. 2002. Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science 298: 1424-1427.
50. Meerveld-Eggink, A., A. M. van der Velden, G. J. Ossenkoppele, A. A. van de Loosdrecht, D. H. Biesma, and G. T. Rijkers. 2009. Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 15: 1523-1530.
51. Willcocks, L. C., A. N. Chaudhry, J. C. Smith, S. Ojha, R. Doffinger, C. J. Watson, and K. G. Smith. 2007. The effect of sirolimus therapy on vaccine responses in transplant recipients. Am. J. Transplant. 7: 2006-2011.
52. Albesiano, E., B. T. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, and N. Chiorazzi. 2003. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood 102: 3333-3339.
53. Endo, Y., H. Marusawa, T. Kou, H. Nakase, S. Fujii, T. Fujimori, K. Kinoshita, T. Honjo, and T. Chiba. 2008. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 135: 889-898, 898.e1-3.
54. Greeve, J., A. Philipsen, K. Krause, W. Klapper, K. Heidorn, B. E. Castle, J. Janda, K. B. Marcu, and R. Parwaresch. 2003. Expression of activationinduced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood 101: 3574-3580.
55. Ramiro, A. R., M. Jankovic, T. Eisenreich, S. Difilippantonio, S. Chen-Kiang, M. Muramatsu, T. Honjo, A. Nussenzweig, and M. C. Nussenzweig. 2004. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118: 431-438.
56. Klemm, L., C. Duy, I. Iacobucci, S. Kuchen, G. von Levetzow, N. Feldhahn, N. Henke, Z. Li, T. K. Hoffmann, Y. M. Kim, et al. 2009. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 16: 232-245.